Skip to main content
AARD
NASDAQ Life Sciences

阿德瓦克生物治疗公司暂停首要的III期药物试验，因心脏安全信号

feedReported by GlobeNewswire
Sentiment info
Negative
Importance info
9
Price
$4.065
Mkt Cap
$88.508M
52W Low
$4.01
52W High
$17.94
Market data snapshot near publication time

summarizeSummary

阿德瓦克生物治疗公司宣布，自愿暂停其III期HERO和OLE试验的招募和给药，用于评估ARD-101治疗普拉德威利症候群，以及其ARD-201肥胖项目。这一决定是在单独的健康志愿者研究中观察到意外、可逆的 cardiac QRS延长，特别是在高剂量时。对于这家临床阶段生物制药公司来说，这是一个重大挫折，引入了其主要管道候选药物的巨大不确定性和延迟。虽然公司注意到这些影响是可逆和剂量依赖的，但由于安全问题而停止III期试验，产生了相当大的监管风险。投资者将密切关注公司和FDA的进一步指导，预计在2026年第二季度，这将是一个关键的催化剂。

在该公告发布时，AARD的交易价格为$4.07，交易所为NASDAQ，所属行业为Life Sciences，市值约为$8850.8万。 52周交易区间为$4.01至$17.94。 这则新闻被评估为消极市场情绪，重要性评分为9/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed AARD - Latest Insights

AARD
Apr 03, 2026, 4:05 PM EDT
Filing Type: 424B5
Importance Score:
9
Aardvark Therapeutics Activates $150M At-The-Market Offering, Signaling Massive Potential Dilution Amidst Trial Pause
Sentiment: Negative
View Wiseek Article
AARD
Mar 23, 2026, 6:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Aardvark Therapeutics Establishes $150M ATM Program Amidst Trial Pause, Signaling Significant Dilution
Sentiment: Negative
View Wiseek Article
AARD
Mar 23, 2026, 5:10 PM EDT
Filing Type: S-3
Importance Score:
9
Aardvark Therapeutics Files $400M Universal Shelf, Including $150M ATM Offering, Amidst Phase 3 Trial Pause
Sentiment: Negative
View Wiseek Article
AARD
Mar 23, 2026, 4:45 PM EDT
Source: Reuters
Importance Score:
8
Aardvark Therapeutics Reports Q4/FY25 Results, Provides Business Updates Following Phase 3 Trial Pause
Sentiment: Neutral
View Wiseek Article
AARD
Mar 23, 2026, 4:19 PM EDT
Filing Type: 10-K
Importance Score:
9
Aardvark Therapeutics Halts All Lead Clinical Trials Due to Cardiac Safety Concerns, Delays Key Data
Sentiment: Negative
View Wiseek Article
AARD
Mar 23, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
9
Aardvark Pauses Phase 3 Trials for ARD-101 Due to Cardiac Safety Concerns; Provides Q4/FY25 Financials
Sentiment: Negative
View Wiseek Article
AARD
Mar 23, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Aardvark Therapeutics Pauses Lead Phase 3 Drug Trial Over Cardiac Safety Signals
Sentiment: Negative
View Wiseek Article
AARD
Feb 27, 2026, 4:27 PM EST
Filing Type: 8-K
Importance Score:
9
Aardvark Therapeutics Pauses Key Phase 3 Trial for ARD-101 Due to Cardiac Safety Observations
Sentiment: Negative
View Wiseek Article
AARD
Feb 27, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
9
Cardiac Safety Concerns Halt Aardvark's Phase 3 Prader-Willi Trial
Sentiment: Negative
View Wiseek Article
AARD
Feb 12, 2026, 8:17 AM EST
Filing Type: 8-K
Importance Score:
8
Aardvark Therapeutics Establishes Dermatology Subsidiary, Appoints CEO, and Expands Executive Team
Sentiment: Positive
View Wiseek Article